Fritextsökning
Artiklar per år
Innehållstyper
-
Marie Gårdmark: ”Vi behöver sätta ord på olika aktörers förväntningar”
”I strävan efter samverkan får vi inte vara tondöva för det som skiljer olika aktörer åt utan snarare använda det till vår fördel”. Det skriver Marie Gårdmark i en krönika.
-
The investor: “The major common diseases are hot again”
She has previously been voted Investor of the Year and will now be moderating The Future of Swedish & Danish Life Science congress. We check the temperature of the industry with Nina Rawal from Trill Impact Advisory.
-
Thumbs down for lecanemab in the EU – “Very surprised”
The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), according to an announcement made by the Agency last week. Bioarctic’s CEO Gunilla Osswald describes the reactions after the announcement as a surprise and disappointment.
-
Healthcare study: Alzheimer’s blood test shows high accuracy
A blood test for identifying Alzheimer’s has now been tested in the general healthcare setting. According to the researchers, the test was 90% accurate in making a diagnosis.
-
Gothenburg, the city of life science – We are ‘Little Boston’
Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other industries for inspiration and knowledge.
-
Danish obesity success causes recruitment problems in southern Sweden
The substantial expansion of Danish Novo Nordisk is affecting companies in southern Sweden, which are finding it increasingly difficult to compete for attractive staff.
-
”Vi har börjat skala upp så fler ska få tillgång till analyser”
Mångsysslaren Richard Rosenquist Brandell har ofta jobbet i tankarna dygnet runt. Han har ett stort engagemang för precisionsmedicin och blodsjukdomar och har fått några av sina bästa idéer på crosstrainern.
-
Nobel Prize winner Torsten Wiesel turns 100: “Old men like me should use their experience to help the young”
In 1955, a young Torsten Wiesel jumped on a boat to the US and embarked on a fabulous career as a neuroscientist, crowned with a Nobel Prize for his work. Now 100 years old, he looks back on an intense life and his upbringing in Stockholm, Sweden, which shaped his desire to help the vulnerable in society.
-
Innovative start-up helps doctors, scientists and industry balance coagulation risks
For many doctors caring for seriously ill patients, for example, in stroke units and cancer wards, maintaining the life-saving balance between bleeding and thrombosis is an ongoing challenge. In the late 1980s, scientists at Maastricht University in the Netherlands developed an innovative method, the thrombin generation assay (TGA), which provides a complete overview of a physiological process crucial for maintaining normal haemostasis.
-
“Conducting research at universities is becoming more and more like working at a research hotel”
The government wants Swedish research to focus on excellence and innovation, but can the two be combined? Life Science Sweden talks to Anna Falk, a professor at Lund University, about research policy, the constant hunt for funding in academia and what constitutes ‘fine research’.
-
Bayer has cut 1,500 roles – so far
German chemical and pharmaceutical group Bayer cut more than 1,500 roles in the first quarter alone– and most of them were management positions.
-
Carl Borrebaeck – professor and serial entrepreneur with a taste for speed
Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borrebaeck, Professor of Immunotechnology at Lund, is not yet satisfied. “We have a new, potentially super exciting project in the pipeline,” he says.
-
Nocebo – the evil twin that makes you feel worse
The placebo effect is well known in healthcare, but not so its opposite: nocebo. “The effect is small, but it can have major repercussions,” says Uppsala researcher Charlotte Blease, co-author of a book on the phenomenon.
-
Study: Popular diabetes treatment is not associated with thyroid cancer
Concerns raised about an association between GLP-1 analogues, used to treat diabetes and obesity, and an increased risk of thyroid cancer are not supported by an extensive Scandinavian study.
-
Settlement of cancer allegations against blockbuster drug
French pharmaceutical company Sanofi has reached a principal agreement in the US on around 4,000 of the cases in which its now withdrawn blockbuster heartburn drug Zantac allegedly had caused cancer.
-
The life science strategy – what the industry wants
The process of updating the national life science strategy has begun at the government’s life science office. According to industry stakeholders, Sweden’s competitiveness, the accessibility of health data and the integration of innovation in healthcare are some of the points that are essential to review.
-
”We need compatibility“
Penilla Gunther, founder of Fokus Patient and chair of the European Patient Safety Foundation, hopes that the forthcoming life science strategy will focus on efficient and secure management of patient data and equal access to medicines.
-
Ny miljonsatsning på life science i Sverige
7,7 miljoner kronor ska nu satsas på ett projekt för att underlätta identifiering och produktion av läkemedel. Bridge Sweden är namnet på projektet och är ett samarbete mellan olika aktörer i Sverige inom life science.
-
Specific proposals and targets top the universities’ desired priorities
What are the universities’ expectations for the update of the national life science strategy? Life Science Sweden posed the question to representatives from Karolinska Institutet and Sahlgrenska Academy.
-
Anna Törner: ”Orphan designation läkemedelsutvecklingens ’petite robe noire’”
Det är så lätt att klamra sig fast vid olika regulatoriska incitament, som orphan designation, utan att egentligen veta vad de innebär och på vilket sätt de kan vara rätt (eller fel), skriver Anna Törner i en krönika.
-
Venom from the deathstalker carries radiopharmaceuticals to the brain
In order to target cancerous brain tumours with radionuclides, the problematic blood-brain barrier must first be crossed. Life Science Sweden has visited a KI researcher who is trialling an unusual approach ‒ using scorpion venom.
-
Dödsskorpionens gift ska transportera radiofarmaka till hjärnan
För att komma åt cancertumörer i hjärnan med radionukleider måste man först ta sig igenom den svårforcerade blod-hjärnbarriären. Life Science Sweden har besökt en KI-forskare som prövar en alldeles egen metod – genom att ta hjälp av gift från skorpioner.
-
“What is important is to create an overview and understanding from different perspectives”
Scientist Jochen Schwenk analyses blood proteins using proteomics to improve our understanding of disease and health. This year, he is moderating the Lab & Diagnostics of the Future event.
-
From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”
A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic region with vaccines during a future pandemic. These are some of the projects underway at NorthX Biologics – under the direction of new CEO Janet Hoogstraate.
BREAKING